Accendatech is dedicated to develop novel therapies to address the unmet medical needs for patients around the world.  To fulfill this commitment, we conduct clinical studies with the leading medical experts worldwide to assess the safety and efficacy of our investigational medicines so that the innovative therapy could obtain the regulatory approval from health authorities and become widely available to patients in need.

     Accendatech would encourage patients to participate in the clinical study of our investigational therapeutics whenever deem to be appropriate. Accendatech is also mindful of the need to access our innovative medicines outside of the formal clinical trial setting on a compassionate use/expanded access basis. Accendatech respects the treatment journey of the patients and their treating physician’s decision, and we would try to accommodate such requests when it is clinically, ethically and practically feasible to do so.

     Accendatech will only consider request for compassionate use/expanded access from a qualified treating physician in accordance with the applicable regional/country-specific laws and regulations. All requests for compassionate use/expanded access will be assessed on case-by-case basis in full consultation with the treating physician.  Informed consent, along with regulatory and institutional approval must be secured by the requesting physician and be provided to Accendatech team for record. Safety data and treatment outcomes should be communicated with Accendatech by the requesting physician in accordance to Accendatech’s compassionate use/expanded access agreement.

     Accendatech reserves the rights to withdraw the compassionate use/expanded access supply on a case-by-case basis.  Further information could be found on Reagan Udall Foundation web site (for US-based patients) or contact Accendatech team by email info@accendatech.com.